Literature DB >> 1233201

Properties of acebutolol in twenty patients with cardiac arrhythmias.

P Biron, A Proulx, L Lapointe, R Nadeau, G Tremblay.   

Abstract

Acebutolol (M & B 17,803 A), a new cardioselective beta-adrenergic blocking agent, was given intravenously to 20 selected patients with various cardiac arrhythmias. Cumulative doses ranging from 12.5 to 50 mg were moderately or highly effective in 4 out of 4 patients with sinus tachycardia, 2 out of 3 patients with premature atrial beats, 3 out of 4 patients with premature ventricular beats, 3 out of 5 patients with atrial fibrillation (one was converted to sinus rhythm) and in 2 out of 3 patients with atrial flutter. The drug was ineffective in one patient with atrial tachycardia. Mild systolic hypotension occured in two patients with recent myocardial infarction and there was some aggravation of a preexisting bronchospasm in a patient with congestive heart failure secondary to hyper-thyroidism. It was concluded that acebutolol is a cardioselective beta-blocker which by intravenous route may be useful in the treatment of selected cardiac arrhythmias.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233201     DOI: 10.1007/bf00616409

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Cardiovascular effects of acebutolol (M & B 17803A), in exercising man; a comparative study with practolol and propranolol.

Authors:  A J Coleman; W P Leary
Journal:  Curr Ther Res Clin Exp       Date:  1972-10

2.  Cardiovascular effects of M & B 17803A in man.

Authors:  W P Leary; A J Coleman
Journal:  S Afr Med J       Date:  1972-08-26

3.  Sectral in the management of angina pectoris.

Authors:  B S Lewis; A Bakst; D J Kitchiner; M S Gotsman
Journal:  S Afr Med J       Date:  1973-08-18

4.  Respiratory effects of acebutolol hydrochloride.

Authors:  W P Leary; A J Coleman; A C Asmal
Journal:  S Afr Med J       Date:  1973-07-21

5.  Haemodynamic effects of a new beta-blocking agent 'Sectral' (M & B 17803A).

Authors:  B S Lewis; A Bakst; A S Mitha; K Purdon; M S Gotsman
Journal:  Br Heart J       Date:  1973-07

6.  Effect of M & B 17803A, a new -adrenoceptor blocking agent, on the cardiovascular responses to tilting and to isoprenaline in man.

Authors:  M F Cuthbert; K Owusu-Ankomah
Journal:  Br J Pharmacol       Date:  1971-11       Impact factor: 8.739

  6 in total
  5 in total

1.  Preliminary observations on the elimination of acebutolol in severe chronic renal failure.

Authors:  C M Kaye; J F Dufton
Journal:  Br J Clin Pharmacol       Date:  1976-02       Impact factor: 4.335

2.  Acebutolol metabolite plasma concentration during chronic oral therapy.

Authors:  R A Winkle; P J Meffin; W B Ricks; D C Harrison
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

3.  Acebutolol in hypertension--double-blind trial against placebo.

Authors:  M A Martin; C A Phillips; A J Smith
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

4.  Cardiovascular effects of acebutolol following coronary artery occlusion and reperfusion in anaesthetized dog.

Authors:  W Chernecki; P K Das; N S Dhalla; G P Sharma
Journal:  Br J Pharmacol       Date:  1978-10       Impact factor: 8.739

5.  Antiarrhythmic effects of acute betablockade with atenolol on supraventricular tachycardias at rest and during exercise.

Authors:  V Hombach; V Braun; H W Höpp; D Gil-Sanchez; D W Behrenbeck; M Tauchert; H H Hilger
Journal:  Klin Wochenschr       Date:  1981-02-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.